{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:08:38Z","timestamp":1791558518493,"version":"4.3.4"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lupus erythematosus is a chronic, heterogenous autoimmune disease driven by a complex interplay of genetic, environmental and hormonal factors, which can manifest as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), or both simultaneously. Plasmacytoid dendritic cells (pDCs) are thought to play a central role in disease pathogenesis following the dysregulated and sustained production of type I interferon (IFN-I), leading to widespread immune system activation and chronic inflammation, resulting in organ and tissue damage characteristic of lupus. While treatment of lupus has shown success with approaches that inhibit the IFN pathway\/IFN-I production, targeting pDCs is of great interest due to their accumulation in lesional tissues and key role in IFN-I production. However, SLE and CLE pathogenesis is clouded by unknowns including limited understanding of the pathophysiological loss of IFN pathway negative feedback, the complexity of IFN production by non-pDC cells (including pDC plasticity and role of different subsets\/states), the role of other cytokines and chemokines in disease pathogenesis, and differences in pDC activation and downstream effects in SLE and CLE. Conceivably, different IFN-I-producing cells may be important in different organs, patients, and disease stages. As understanding of the role of pDCs in IFN-I production evolves, there is great potential to develop more targeted and effective treatments that can enhance patient outcomes to ensure pathophysiological and chronic inflammation is negated while maintaining physiological immunity to infection.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1807771","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:12:55Z","timestamp":1779354775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding"],"prefix":"10.3389","volume":"17","author":[{"given":"Victoria P.","family":"Werth","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, and Corporal Michael J. Crescenz VA Medical Center","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"R\u00f6nnblom","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Wenzel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Bonn","place":["Bonn, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K.","family":"Moseley","sequence":"additional","affiliation":[{"name":"Biogen, Global Medical Affairs Immunology","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Gaiha-Rohrbach","sequence":"additional","affiliation":[{"name":"Biogen, Global Medical Affairs Immunology","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Biogen, Immunology Research Unit","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Barbey","sequence":"additional","affiliation":[{"name":"Clinical Development, Multiple Sclerosis and Immunology Department Unit","place":["Biogen, Baar, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Grogan","sequence":"additional","affiliation":[{"name":"Biogen, Immunology Research Unit","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colonna","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Washington University in Saint Louis","place":["Saint Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01898-7","article-title":"The immunology of systemic lupus erythematosus","volume":"25","author":"Tsokos","year":"2024","journal-title":"Nat Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0065-2776(06)92001-x","article-title":"Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease","volume":"92","author":"Fairhurst","year":"2006","journal-title":"Adv Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001114","article-title":"Clinical trial outcomes for SLE: what we have and what we need","volume":"11","author":"Arnaud","year":"2024","journal-title":"Lupus Sci Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3899\/jrheum.220089","article-title":"Cutaneous involvement in systemic lupus erythematosus: a review for the rheumatologist","volume":"50","author":"Stull","year":"2023","journal-title":"J Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6610509","article-title":"Cutaneous manifestations of \"lupus\": systemic lupus erythematosus and beyond","volume":"2021","author":"Cooper","year":"2021","journal-title":"Int J Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13082419","article-title":"The spectrum of cutaneous manifestations in lupus erythematosus: a comprehensive review","volume":"13","author":"Fija\u0142kowska","year":"2024","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320951842","article-title":"Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model","volume":"29","author":"Ogunsanya","year":"2020","journal-title":"Lupus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.897987","article-title":"The burden of living with cutaneous lupus erythematosus","volume":"9","author":"Drenkard","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170209","article-title":"Factors associated with health-related quality of life in Mexican lupus patients using the LupusQol","volume":"12","author":"Etchegaray-Morales","year":"2017","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae374","article-title":"Monoclonal antibodies for the management of cutaneous lupus erythematosus: an update on the current treatment landscape","volume":"50","author":"Jafari","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B15","unstructured":"BENLYSTA highlilghts of prescribing information\n          \n          2024"},{"key":"B16","unstructured":"BENLYSTA summary of product characteristics\n          \n          2025"},{"key":"B17","unstructured":"SAPHNELO highlights of prescribing information\n          \n          2024"},{"key":"B18","unstructured":"SAPHNELO summary of product characteristics\n          \n          2025"},{"key":"B19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus \u2013 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2014.888415","article-title":"Therapeutic targeting of the BAFF\/APRIL axis in systemic lupus erythematosus","volume":"18","author":"Stohl","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"B21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/1744666X.2023.2268284","article-title":"Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus","volume":"20","author":"Gensous","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.39085","article-title":"Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus","volume":"67","author":"Vital","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2212154","article-title":"Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus","volume":"32","author":"Cho","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: what have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2023.2264023","article-title":"A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7\/8 antagonist through academia-industry-government collaboration","volume":"47","author":"Tanaka","year":"2024","journal-title":"Immunol Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01152-2","article-title":"Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy","volume":"20","author":"Ghodke-Puranik","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","article-title":"Plasmacytoid dendritic cells: development, regulation, and function","volume":"50","author":"Reizis","year":"2019","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00774-8","article-title":"Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions","volume":"24","author":"Niebel","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01167-5","article-title":"The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond","volume":"21","author":"Ngo","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.11.6592","article-title":"Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands","volume":"173","author":"Kohrgruber","year":"2004","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121103","article-title":"Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells","volume":"210","author":"Segura","year":"2013","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1139","article-title":"Plasmacytoid dendritic cell biology and its role in immune-mediated diseases","volume":"9","author":"Ye","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00826-z","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41590-017-0012-z","article-title":"Diversification of human plasmacytoid predendritic cells in response to a single stimulus","volume":"19","author":"Alculumbre","year":"2018","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-090122-041105","article-title":"Ontogeny and function of plasmacytoid dendritic cells","volume":"42","author":"Adams","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ni1141","article-title":"Plasmacytoid dendritic cells in immunity","volume":"5","author":"Colonna","year":"2004","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.37821","article-title":"Disease mechanisms in rheumatology\u2014tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases","volume":"65","author":"Eloranta","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nri3865","article-title":"The multifaceted biology of plasmacytoid dendritic cells","volume":"15","author":"Swiecki","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800933","article-title":"Triggering of the cGAS-STING pathway in human plasmacytoid dendritic cells inhibits TLR9-mediated IFN production","volume":"205","author":"Deb","year":"2020","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.915828","article-title":"Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus","volume":"9","author":"Fetter","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1554492","article-title":"Sequential activation of conventional and plasmacytoid dendritic cells in autoimmune pancreatitis and systemic lupus erythematosus: similarities and dissimilarities","volume":"16","author":"Hara","year":"2025","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1823","article-title":"BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha\/beta induction","volume":"194","author":"Dzionek","year":"2001","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312404121","article-title":"A type I interferon regulatory network for human plasmacytoid dendritic cells based on heparin, membrane-bound and soluble BDCA-2","volume":"121","author":"Venegas-Solis","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3296","article-title":"Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG","volume":"171","author":"B\u00e5ve","year":"2003","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/art.11225","article-title":"Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"48","author":"Blomberg","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00196-08","article-title":"CD4 binding affinity determines human immunodeficiency virus type 1-induced alpha interferon production in plasmacytoid dendritic cells","volume":"82","author":"Haupt","year":"2008","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cells8090963","article-title":"Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus","volume":"8","author":"Chyuan","year":"2019","journal-title":"Cells"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073290","article-title":"IL-10 in systemic lupus erythematosus: balancing immunoregulation and autoimmunity","volume":"26","author":"Richter","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01970","article-title":"Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands","volume":"8","author":"Metzemaekers","year":"2017","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12173","article-title":"Plasmacytoid dendritic cell heterogeneity is defined by CXCL10 expression following TLR7 stimulation","volume":"96","author":"Marsman","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.09.002","article-title":"Antigen-presentation properties of plasmacytoid dendritic cells","volume":"29","author":"Villadangos","year":"2008","journal-title":"Immunity"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.10.039","article-title":"Plasmacytoid dendritic cells are not major producers of type 1 IFN in cutaneous lupus: an in-depth immunoprofile of subacute and discoid lupus","volume":"144","author":"Vazquez","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07671-y","article-title":"Plasmacytoid dendritic cells control homeostasis of megakaryopoiesis","volume":"631","author":"Gaertner","year":"2024","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01222","article-title":"What makes a pDC: recent advances in understanding plasmacytoid DC development and heterogeneity","volume":"10","author":"Musumeci","year":"2019","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101048","article-title":"Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9","volume":"207","author":"Guiducci","year":"2010","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132620","article-title":"Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model","volume":"211","author":"Rowland","year":"2014","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/art.38298","article-title":"Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic lupus erythematosus","volume":"66","author":"Yokogawa","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/art.38989","article-title":"Sialic acid-binding immunoglobulin-type lectin H-positive plasmacytoid dendritic cells drive spontaneous lupus-like disease development in B6.Nba2 mice","volume":"67","author":"Davison","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132522","article-title":"Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"211","author":"Sisirak","year":"2014","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2010.05.004","article-title":"Trafficking properties of plasmacytoid dendritic cells in health and disease","volume":"31","author":"Sozzani","year":"2010","journal-title":"Trends Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren's syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B65","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and type 1 interferons","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam8458","article-title":"Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8","volume":"10","author":"Ah Kioon","year":"2018","journal-title":"Sci Transl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221085","article-title":"Chronic activation of pDCs in autoimmunity is linked to dysregulated ER stress and metabolic responses","volume":"219","author":"Chaudhary","year":"2022","journal-title":"J Exp Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I interferon signature in the initiation of the immune response in vitiligo","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh115","article-title":"Characterization of plasmacytoid dendritic cells in inflammatory arthritis synovial fluid","volume":"43","author":"Van Krinks","year":"2004","journal-title":"Rheumatol (Oxford)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.070703","article-title":"Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles","volume":"172","author":"Lebre","year":"2008","journal-title":"Am J Pathol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1037408","article-title":"Characterization of B cells in lupus erythematosus skin biopsies in the context of different immune cell infiltration patterns","volume":"9","author":"de Vos","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2009.06.013","article-title":"Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage","volume":"214","author":"Vermi","year":"2009","journal-title":"Immunobiology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13075-017-1441-7","article-title":"Enhanced IFN-\u03b1 production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus","volume":"19","author":"Murayama","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404719","article-title":"Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms","volume":"7","author":"Pellerin","year":"2015","journal-title":"EMBO Mol Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12416","article-title":"Plasmacytoid dendritic cells in hypertrophic discoid lupus erythematosus: an objective evaluation of their diagnostic value","volume":"42","author":"Walsh","year":"2015","journal-title":"J Cutan Pathol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/science.1064890","article-title":"Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus","volume":"294","author":"Blanco","year":"2001","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8442","article-title":"Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/jci124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","first-page":"73ra19","DOI":"10.1126\/scitranslmed.3001180","article-title":"Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus","volume":"3","author":"Lande","year":"2011","journal-title":"Sci Transl Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101530","article-title":"STING mediates lupus via the activation of conventional dendritic cell maturation and plasmacytoid dendritic cell differentiation","volume":"23","author":"Thim-Uam","year":"2020","journal-title":"iScience"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.939594","article-title":"Current concepts of photosensitivity in cutaneous lupus erythematosus","volume":"9","author":"Klein","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-016-1421-4","article-title":"Cause and consequences of the activated type I interferon system in SLE","volume":"94","author":"Eloranta","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.164875","article-title":"NCF1-dependent production of ROS protects against lupus by regulating plasmacytoid dendritic cell development and functions","volume":"8","author":"Luo","year":"2023","journal-title":"JCI Insight"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.37349\/ei.2025.1003222","article-title":"Cutaneous lupus erythematosus: insights from molecular pathogenesis to targeted therapies","volume":"5","author":"Alduraibi","year":"2025","journal-title":"Explor Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.12.012","article-title":"Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus","volume":"65","author":"Kreuter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew427","article-title":"Pathways leading to an immunological disease: systemic lupus erythematosus","volume":"56","author":"Zharkova","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000739","article-title":"Cutaneous and systemic connections in lupus","volume":"32","author":"Maz","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802008","article-title":"CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions","volume":"182","author":"Matsui","year":"2009","journal-title":"J Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610630114","article-title":"A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag3009","article-title":"Mapping the human DC lineage through the integration of high-dimensional techniques","volume":"356","author":"See","year":"2017","journal-title":"Science"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190811","article-title":"Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation","volume":"217","author":"Chen","year":"2019","journal-title":"J Exp Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0731-4","article-title":"The activation trajectory of plasmacytoid dendritic cells in vivo during a viral infection","volume":"21","author":"Abbas","year":"2020","journal-title":"Nat Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02234-3","article-title":"TNF and type I interferon crosstalk controls the fate and function of plasmacytoid dendritic cells","volume":"26","author":"Arroyo Hornero","year":"2025","journal-title":"Nat Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01545-7","article-title":"Transitional dendritic cells are distinct from conventional DC2 precursors and mediate proinflammatory antiviral responses","volume":"24","author":"Sulczewski","year":"2023","journal-title":"Nat Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102865","article-title":"Recent advances in cutaneous lupus","volume":"132","author":"Maz","year":"2022","journal-title":"J Autoimmun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2010.01587.x","article-title":"Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner's lymphocytic infiltrate of the skin and cutaneous lupus erythematosus","volume":"37","author":"Tomasini","year":"2010","journal-title":"J Cutaneous Pathol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.immuni.2017.11.001","article-title":"High-dimensional phenotypic mapping of human dendritic cells reveals interindividual variation and tissue specialization","volume":"47","author":"Alc\u00e1ntara-Hern\u00e1ndez","year":"2017","journal-title":"Immunity"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/his.13817","article-title":"Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T cell lymphoma","volume":"74","author":"Chen","year":"2019","journal-title":"Histopathology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2011.01779.x","article-title":"Hypertrophic lupus erythematosus: the diagnostic utility of CD123 staining","volume":"38","author":"Ko","year":"2011","journal-title":"J Cutan Pathol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405249","article-title":"Comprehensive analysis of human monocyte subsets using full-spectrum flow cytometry and hierarchical marker clustering","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00275","article-title":"Effect of in vivo hydroxychloroquine and ex vivo anti-BDCA2 mAb treatment on pDC IFN\u03b1 production from patients affected with cutaneous lupus erythematosus","volume":"10","author":"Gardet","year":"2019","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.4386","article-title":"AB0444 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and\/or CLE (WILLOW)","volume":"81","author":"Morand","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B109","first-page":"1542","article-title":"Efficacy and safety results from a phase 2 trial of daxdilimab in patients with systemic lupus erythematosus","volume":"76","author":"Khosroshahi","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107173","article-title":"CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses","volume":"26","author":"Monaghan","year":"2023","journal-title":"iScience"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005072","article-title":"Fine-tuning SLE treatment: the potential of selective TYK2 inhibition","volume":"10","author":"Satoh-Kanda","year":"2024","journal-title":"RMD Open"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.141","article-title":"Efficacy and safety of oral deucravacitinib in patients with cutaneous manifestations of lupus erythematosus: results from PAISLEY CLE, a global, randomized, placebo-controlled, phase 2 trial","volume":"84","author":"Merola","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.842","article-title":"Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8","volume":"9","author":"Port","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/nature09102","article-title":"TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus","volume":"465","author":"Guiducci","year":"2010","journal-title":"Nature"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.immuni.2018.03.020","article-title":"Self-renewal and toll-like receptor signaling sustain exhausted plasmacytoid dendritic cells during chronic viral infection","volume":"48","author":"Macal","year":"2018","journal-title":"Immunity"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218439","article-title":"Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma","volume":"80","author":"Ross","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B120","unstructured":"A study to learn about the safety of litifilimab (BIIB059) injections and whether they can improve symptoms of adult participants who have systemic lupus erythematosus (TOPAZ-1)\n          \n          2021"},{"key":"B121","unstructured":"A study to learn about the safety of litifilimab (BIIB059) injections and whether they can improve symptoms of adult participants who have systemic lupus erythematosus (TOPAZ-2)\n          \n          2021"},{"key":"B122","unstructured":"A 2-part study to learn whether litifilimab (BIIB059) injections can improve symptoms of adult participants who have active cutaneous lupus erythematosus (AMETHYST)\n          \n          2022"},{"key":"B123","unstructured":"A long-term extension study to learn more about the safety of litifilimab (BIIB059) injections and whether they can improve symptoms of adult participants who have active cutaneous lupus erythematosus (AMETHYST LTE)\n          \n          2023"},{"key":"B124","unstructured":"An extension study to learn more about the long-term safety of litifilimab (BIIB059) injections and whether they can improve symptoms of adult participants who have systemic lupus erythematosus (EMERALD)\n          \n          2022"},{"key":"B125","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity","volume":"11","author":"Psarras","year":"2020","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2263","article-title":"Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation","volume":"14","author":"Billi","year":"2022","journal-title":"Sci Transl Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1998.0215","article-title":"Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells","volume":"11","author":"Cederblad","year":"1998","journal-title":"J Autoimmun"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1916897117","article-title":"Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus","volume":"117","author":"Goel","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181359","article-title":"A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection","volume":"216","author":"Barrat","year":"2019","journal-title":"J Exp Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30330","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17161","article-title":"An update on clinical trials for cutaneous lupus erythematosus","volume":"51","author":"Xie","year":"2024","journal-title":"J Dermatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052505","article-title":"Type I interferons in systemic lupus erythematosus: a journey from bench to bedside","volume":"23","author":"Sim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B134","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13073-017-0467-4","article-title":"A practical guide to single-cell RNA-sequencing for biomedical research and clinical applications","volume":"9","author":"Haque","year":"2017","journal-title":"Genome Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2240959","article-title":"A review of genetic risk in systemic lupus erythematosus","volume":"19","author":"Guga","year":"2023","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807771\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:13:01Z","timestamp":1779354781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807771\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":135,"alternative-id":["10.3389\/fimmu.2026.1807771"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1807771","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1807771"}}